Company Information
CIN
Status
Date of Incorporation
08 August 1973
State / ROC
/ ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
Paid Up Capital
239,130,000
Authorised Capital
500,000,000
Directors
Sudha Ravi
Director/Designated Partner
about 2 years ago
about 2 years ago
Basudeo Narayan Singh
Director/Designated Partner
about 2 years ago
about 2 years ago
Aniruddha Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Sujjain Talwar
Director/Designated Partner
over 2 years ago
over 2 years ago
Madhurima Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Narendra Aneja
Director/Designated Partner
over 2 years ago
over 2 years ago
Divya Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Sangeeta Kapiljit Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Satish Kumar Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Mritunjay Kumar Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Dheeraj Sharma
Director/Designated Partner
over 2 years ago
over 2 years ago
Lalan Kumar Singh
Beneficial Owner
over 4 years ago
over 4 years ago
Archana Singh
Beneficial Owner
over 4 years ago
over 4 years ago
Meghna Singh
Director/Designated Partner
over 4 years ago
over 4 years ago
Inderjit Paramjitsingh Arora
Director/Designated Partner
over 4 years ago
over 4 years ago
Sarvesh Singh
Director/Designated Partner
about 6 years ago
about 6 years ago
Premlata Singh .
Beneficial Owner
about 6 years ago
about 6 years ago
Sarandhar Singh
Beneficial Owner
about 6 years ago
about 6 years ago
Srinivas Balmiki Prasad Singh
Director/Designated Partner
about 6 years ago
about 6 years ago
Arun Kumar Purwar
Director/Designated Partner
over 10 years ago
over 10 years ago
Sandeep Singh
Director/Designated Partner
over 10 years ago
over 10 years ago
Laxmana Ranjal Shenoy
Director/Designated Partner
over 10 years ago
over 10 years ago
Rajesh Matasevak Dubey
Manager/Secretary
over 11 years ago
over 11 years ago
Balmiki Prasad Singh
Beneficial Owner
over 15 years ago
over 15 years ago
Manish Narang
Company Secretary
almost 19 years ago
almost 19 years ago
Past Directors
Dhananjay Kumar Singh
Managing Director
over 10 years ago
over 10 years ago
Samprada Singh
Director
over 10 years ago
over 10 years ago
Akhouri Maheshwar Prasad
Director
over 10 years ago
over 10 years ago
Mangaldas Chhaganlal Shah
Director
about 18 years ago
about 18 years ago
Nawal Kishore Singh
Whole Time Director
over 18 years ago
over 18 years ago
Patents
The present invention relates to a process for the production of stable fructooligosaccharides by using fructosyltransferase from Aureobasidium species immobilized in sodium alginate.
There is provided a process of preparing 3-(2-Imidazoline-2-ylthio)indole hydrochloride(Tinazoline)by considering indole and ethylene thiourea in alcoholic solvent using iodine and alkali iodide solution.The resulting materialis purified using organic solvent.This material is further treared with alkali and resultan...
There is provided bovine oestrogen conjugates in high yield and purity derived from bovine urine.Also there is provided process for the preparation of obvine oestrogen conjuates.Bovine urine is concentrated and extracted with an organic solvent of short carbon chain length followed by drying of the solvent extrac...
The present invention relates to an abuse-proofed, extended release pharmaceutical composition and process of preparation thereof, for oral administration comprising; Tapentadol or a pharmaceutically acceptable salt thereof; as an active ingredient; at least one Hydrogenated vegetable oil as an extended release agen...
The present invention provides particulate rasagiline mesylate having a particle size of about 255 microns to about 590 microns. Particularly it relates to a process of preparing rasagiline mesylate having large particle size by crystallisation techniques and devoid of comminution techniques to control particle size...
The present invention relates to a clear, stable pharmaceutical composition in the form of solution for topical administration in the treatment of Vitiligo comprising: Active fragment of bFGF in the range of 0.02 to 0.5 % w/w; at least one penetration enhancing agent in the range of 10-40 % w/v; at least one non-ion...
The present invention relates to atovaquone prodrug compound of formula (I). Accordingly, present invention provides a process involving condensation of Atovaquone (II) with 5-methyl-4-chloromethyl dioxalone (III) in suitable solvent system and optionally followed by distillation and crystallization to provide Atova...
The present invention relates to a novel process for the optical purification of enantiomerically enriched 2-(pyridinylmethylsulphinyl)-lH-benzimidazole compounds and their pharmaceutically acceptable salts of Formula 1
wherein R1 to R4 may be selected from H, linear or
branched (1-4 C) alkyl, linear or branche...
The present invention relates to an improved process for the preparation of angiotensin receptor antagonists and intermediates thereof. Particularly the present invention relates to an improved process for the preparation of N-(l-oxopentyl)-N-[[2'-(lH-tetrazol-5-yl) [1, l'-biphenyl]-4-yl] methyl]-L-valine of Formula...
The present invention may be summarized as follows:
A process for preparing an oral formulation comprising an acid-sensitive benzimidazole drug comprising:
(a) (i) Depositing a stabilizer layer, free of the said drug and comprising an alkaline
material; or (ii) a drug layer, free of an alkaline material and compr...
The present invention provides an improved process for the preparation of (E)-entacapone substantially free of Z isomer by employing an ion exchange resin as catalyst during the condensation of 3. 4-dihydroxy 5-nitrobenzaldehycle or 3-alkoxy 4-hydroxy 5-nitrobenzaldehyde with N. N-dietliylcyano acetamide in an organ...
The present invention relates to a controlled release, multiple unit pharmaceutical composition comprising a plurality of the same type of controlled release units, wherein each unit comprises of a core, a first coating layer surrounding the outer surface of the said core, wherein the coating layer comprises carvedi...
The technical field of present invention relates to a stable duloxetine hydrochloride composition wherein the formulation is stabilized using physical barriers of coating between the drug layer and the enteric layer. The invention provides preparation of duloxetine enteric formulation comprising a drug layer, a firs...
The present invention relates to a stable oral pharmaceutical composition comprising rasagiline or its pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier, wherein the carrier is selected from a polyhydric alcohol, disaccharide(s) and polysaccharide(s) or mixtures thereof; and wherein...
The present invention relates to Stable pharmaceutical composition comprising lanthanum carbonate and a lubricant selected from sodium stearyl fumarate, zinc stearate, calcium stearate, stearic acid or mixtures thereof.
The present invention relates to a process for preparing Enteric coated pharmaceutical compositions of mycophenolate, a salt or a prodrug thereof, wherein the compositions are formulated to release at most about 10 % w/w of mycophenolate in an acidic medium of 0.1 N HC1, pH 1.2.
The present invention relates to a taste masked pharmaceutical composition of cefuroxime axetil or its pharmaceutically acceptable derivatives comprising an ion exchange resin and a lipid or a mixture of lipid or a polymer or a or a mixture of polymers or a mixture of lipid and polymer.
The present invention relates to a parenteral composition of satranidazole comprising satranidazole or its pharmaceutical acceptable salt, one or more solvents and one or more glycols.
The present invention relates to an improved process for the preparation of cis nucleosides and its pharmaceutical compositions thereof. The intermediate compound of formula II, dissolved in a suitable solvent and alkali carbonate or bicarbonate base with a reducing agent, followed by treatment with organic or miner...
This invention is based on the surprising finding that when ibuprofen of a particular particle size is used, the process time of preparing the liquid fill composition is drastically reduced.
The present invention relates to an ibuprofen liquid fill formulation, wherein the said liquid fill comprises ibuprofen with ...
The present invention relates to a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt. More particularly it relates to a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and suitable aluminium compounds in an am...
The present invention relates to a process for preparing stable isomaitooligosaccharides comprising an enzymatic transfer reaction in the presence of glucansucrase between maltose and isomalto-oligosaccharides, wherein the said process comprises of about 0.025% to about 0.05% v/v solution of glucansucrase and about ...
The present invention relates to preparation of napthoquinone compounds by using a 2,3-dihalonapthoquinone intermediate.
The present invention relates to a process for the preparation and purification of 5-[2-[4-(l, 2- benzisothiazol-3-yl)-l-piperazinyl] ethyl]-6- chloro-1, 3-dihydro-2 H -indol-2-one, also known as ziprasidone.
An oral medicinal formulation for the treatment of diabetes mellitus is disclosed. The formulation comprises Cinnamon in an amount of about 1 to 70 % of the mass of the formulation; Zinc ion source in the form of na"noparticles that are substantially non-aggregated, in an amount of about 0.1 to 20 % of the mass of t...
The present invention relates to a stable oral pharmaceutical composition
comprising atorvastatin or its pharmaceutically acceptable salt and suitable
alkali metal salt additives in an amount of more than 5 % w/w so as to
prevent degradation of the atorvastatin or its pharmaceutically acceptable
salt.
...
The present invention relates to a sweetener composition comprising sucralose and a sweetness enhancing agent selected from the group consisting of fructooligosaccharide, neotame, stevia, neohesperidine,saccharides and thaumatin, wherein the inter se ratios of the sucralose to the sweetness enhancing agent is in the...
The present invention relates to compact pharmaceutical compositions of lanthanum carbonate comprising diluents in an amount ranging from about 30 % w/w to about 40 % w/w of the composition.
"A Stable Injectable Pharmaceutical Composition Of Aceclofenac And Process For Preparing Therefore".
The present invention relates to a stable injectable pharmaceutical composition comprising an aqueous solution of arginine and aceclofenac in the molar ratio of arginine to aceclofenac in the range of about 1.1:1 to about 3.4:1, having pH of about 6.5 to about 8.7, wherein the said aqueous solution is lyophilized.
...
The present invention relates to a process for the preparation of amorphous carvedilol phosphate comprising; adding carvedilol base or carvedilol phosphate to a solvent consisting of water miscible cyclic ether(s) or aliphatic nitrile(s) or a mixture thereof and optionally adding water; optionally. adding orthophosp...
The present invention relates to a novel process for the preparation of paliperidone by hydrolysis of 9-O-acylated paliperidone .In a preferred embodiment of the present invention, Paliperidone Form (D) of purity of about 98% or more was obtained by basic hydrolysis of 9-O-Acetyl Paliperidone.
The present invention relates to a process for preparing risedronic acid comprising the step of combining a 3 pyridyl acetic acid or a salt thereof, phosphorous acid, and a halophosporous compound selected from PC13, PC15, POCI3, PBr3, POBr3,and PBr5 in the presence of a diluent that is either a bicyclic aliphatic h...
The present invention is a pharmaceutical composition comprising mycophenolate mofetil in an amount of about 75 to about 200 mg/ml and a suspending agent(s) in an amount of less than 1 mg/ml, as a dry formulation suitable, when constituted with water, for forming a suspension for oral administration, where mg/ml rep...
The present invention relates to a process of preparing bisphosphonic acids and salts thereof.
The present invention describes a fat substitute formed by the conjugation of fructo-oligosaccharides with omega fatty acids. The fat substitute of the present invention imparts heat stability to the omega fatty acid, shows synergy in the omega fatty acid content and also offers health benefits. The present inventio...
Abstract
The present invention is directed to an improved process for the preparation of substituted quifioxalmes by cyclization of the corresponding dianiline in the presence of ion exchange resin.
The technical field of present invention relates to stable solid dosage forms comprising 2-20% weight of amlodipine besylate, 10-70% by weight polyols, and at least a known pharmaceutical excipient having levels of impurity D ({3-ethyl-5-methyl-2-&isqb; (2-aminoethoxy) methyl] 4-(2-chlorophenyl) 6-methylpyridin...
The present invention relates to a pharmaceutical gastro-retentive matrix composition for controlled release of satranidazole in the gastrointestinal tract comprising satranidazole or its pharmaceutically acceptable salt, a gel forming polymer and a gas generating component.
The present invention is directed to a process for the preparation of N-propargyl 1-amino indane and pharmaceutically acceptable salts thereof by a process comprising
a) providing a reaction mixture comprising N-propargyl-1-amino indane and/or a salt thereof,
b) purifying N-propargyl-1 -amino indane free base excl...
The present invention relates to a sweetener composition comprising crystals of sucrose, with sucralose incorporated in the sucrose.
The present invention provides a stable transmucosal pharmaceutical composition of Levocetirizine or pharmaceutically acceptable salt thereof and and processes for preparing thereof. Further the present invention specifically relates to a method of such composition for alleviating associated symptoms of the allergic...
There is provided a process of preparing 3-(2-tmidazline-2-ylthio) indole hydrochloride (Tinazoline) by condensing indole and ethylene thiourea in alcoholic solvent using iodine and alkali iodide solution. The resulting material is purified using organic solvent. This material is further treated with the alk...
A process for taste masking of bitter drugs is disclosed. The process comprises the steps of [i] selecting a lipidic, hydrobhobic coating composition; [ii] selecting a bio compatible solvent, having a low boiling point, in which the said drugs are insoluble but in which the coating composition is soluble; [i...
ABSTRACT
The present invention is directed to a novel process for the preparation of Apremilast in amorphous
form directly from the crude reaction mixture comprising the final stage condensation of a 3-acetamidophthalie anhydride and a chiral amino acid salt of (S)-2-(3-ethoxy~4-methoxyphenyl)-1-(methylsulfonyl)-e...
ABSTRACT
The present invention relates to a stable pharmaceutical formulation comprising from about 0.1 to about 5% w/w dronabinol, at least about 40% w/w or more of water buffered to a pH from about 6 to about 7.5, from about 15 to about 65% w/w alcohol, from about 3 to about 10 % w/w propylene glycol, from about ...
The present invention relates to a stable sublingual film comprising a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and a non-aqueous solvent, wherein the formulation does...
ABSTRACT
The invention relates to a liquid pharmaceutical composition comprising from about 0.1 to about 10% w/w dronabinol, at least about 50% w/w or more of water, from about 2 % w/w or less ethanol, from about 1 to about 40% w/w castor oil or derivatives thereof, wherein the liquid composition is stable at room,...
The present invention relates to a novel process tor the preparation of
pharmaceutical grade ferric citrate with controlled surface area by a process comprising the steps:
(a) adding an alkaline metal hydroxide solution to a solution of aqueous ferric chloride in the presence of diatomaceous earth; and isolating f...
A stable pharmaceutical composition comprising a core comprising Ibuprofen or salt thereof and a shell comprising famotidine or salt thereof wherein there is barrier layer separating Ibuprofen core and Famotidine shell. The configuration of the pharmaceutical composition of the present invention unexpectedly results...
The present invention relates to the polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof. Particularly, the present invention relates to crystalline hydrate and crystalline anhydrous forms of Amlodipine benzoate. The present invention also relates to the processes for the preparation of ...
The present invention relates to a topical pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt thereof and a corticosteroid or a pharmaceutically acceptable salt thereof, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal conge...
ABSTRACT EMITTER AND DRIP IRRIGATION TUBE This emitter (120) has double ridges provided around a hole (173) which forms a portion of a flow path between a reduced-pressure flow path and a discharge part. A first ridge (174), which is the outermost ridge, is provided with four first grooves (177) which intersect said...
The present invention relates to a stable liquid pharmaceutical composition comprising enalapril, one/more pharmaceutically acceptable excipients comprising one/more preservatives and one or more sugar and/or sugar alcohol. Specifically, the oral liquid pharmaceutical composition comprising enalapril, one/more parab...
The present invention relates to a solid oral formulation of (R)-2-amino-3-phenylpropyl carbamate, the formulation comprising (a) (R)-2-amino-3-phenylpropyl carbamate in a concentration of about 60-85% w/w, (b) binder in a concentration of about 5-30% w/w and (c) one/more pharmaceutically acceptable excipients.
...
ABSTRACT
The present invention relates to a topical, foamable composition comprising Luliconazole, and pharmaceutically acceptable excipients selected from group consisting of surfactant, preservative, chelating agent, viscosifier, suspending agent, conditioner, emollient, pH adjuster and mixture thereof. The sai...
The present invention relates to a stable pharmaceutical compositions comprising therapeutically effective amount of Azilsartan medoxomil or a pharmaceutically acceptable salt thereof as a first active agent, optionally a second active agent(s), an antioxidant and one or more other pharmaceutically acceptable excipi...
The present invention provides an improved scalable process for preparation of mixed oxybate salts. More particularly, the present invention provides a process of preparation of a mixture of sodium, potassium, magnesium and calcium oxybate salts. Further, the present invention provides polymorphs of each of the indi...
The present invention relates to a stable pharmaceutical composition comprising dipeptidylpeptidase-4 (DPP-4) inhibitor, sodium-glucose linked transporter 2 (SGLT-2) inhibitor, and biguanide or a pharmaceutically acceptable salt thereof. The present invention, more particularly, relates to bi-layer tablet formulatio...
The present invention relates to compositions of tacrolimus or an analogue thereof and having enhanced bioavailability, more specifically stable extended release compositions comprising tacrolimus or an analogue thereof and pharmaceutically acceptable excipients and method of manufacturing thereof. The invention als...
The present invention relates to a topical composition comprising roflumilast, N-oxide of roflumilast or salts thereof and process of preparation of same. The invention also relates to a method of treatment of a dermal disease by topical administration of said topical composition.
PHARMACEUTICAL COMPOSITION COMPRISING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE
The present invention relates to stable immediate release pharmaceutical composition comprising (R)-2-amino-3-phenylpropyl carbamate (APC) and one/more pharmaceutically acceptable excipients. Specifically, the stable immediate release phar...
The present invention relates to Topiramate extended-release composition. The present invention specifically relates to extended-release composition comprising Topiramate and pharmaceutically acceptable excipients, wherein said composition is in the form of tablet or capsule. The present invention specifically relat...
ABSTRACT OF THE INVENTION
STABLE PHARMACEUTICAL COMPOSITION OF RELUGOLIX
The present invention relates to a stable pharmaceutical composition comprising relugolix or a pharmaceutically acceptable salt thereof; wherein the composition is devoid of sugar alcohols. The present invention, more particularly, relat...
ABSTRACT
NOVEL SALTS OF ARAMCHOL AND PROCESS THEREOF
The present invention provides novel salts of Aramchol with an improved water solubility, physicochemical stability and dissolution characteristics. Particularly, the present invention provides sodium, potassium, magnesium, calcium and zinc salts of Aramchol a...
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF LUMATEPERONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS
The present invention provides an improved process for the preparation of Lumateperone or its pharmaceutically acceptable salts of formula I substantially free from organic impurities. More particularly, the...
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF ARAMCHOL
The present invention provides an improved process for the preparation of Aramchol of formula I. More particularly, the present invention provides a novel intermediate of formula VI and their use in the preparation of Aramchol of formula I. The present...
The present invention provides a stable pharmaceutical composition comprising Saroglitazar or a pharmaceutically acceptable salt thereof. Further, the present invention specifically relates to tablet formulation comprising Saroglitazar or a pharmaceutically acceptable salt thereof, and the process of preparation the...
Stable Pharmaceutical Compositions of Carbidopa and Levodopa
The present invention relates to a stable pharmaceutical composition comprising (a) a controlled release component comprising a core containing levodopa and one or more pharmaceutically acceptable excipients coated with a layer of release controlling a...
The present invention relates to a pharmaceutical composition for oral administration comprising: a) about 5 % w/w to about 40 % w/w of lumateperone or pharmaceutically acceptable salt thereof; b) about 50 % w/w to about 95 % w/w of mannitol; c) about 1 % w/w to about 10 % w/w of croscarmellose sodium; d) about 0.1 ...
The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with...
The present invention relates to a composition comprising Mesdopetam alone or in combination with proton pump inhibitor which can be administered either separately i.e. by co-administration or in a fixed dose combination (FDC) in the treatment of gastrointestinal and related disorders. The present invention provides...
A STABLE ORAL PHARMACEUTICAL COMPOSITION OF ASPIRIN AND PANTOPRAZOLE
ABSTRACT
The present invention relates in part to a multiparticulate dosage form comprising aspirin and pantoprazole or a pharmaceutically acceptable salt thereof. The present invention, more particularly, relates to capsule formulation compri...
A STABLE PHARMACEUTICAL COMPOSITION OF A SMOKING CESSATION DRUG
Abstract
The present invention relates to a stable pharmaceutical composition comprising a smoking cessation drug and process for the preparation thereof. This invention more particularly relates to a stable pharmaceutical composition comprising a smo...
STABLE PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID
ABSTRACT
The present invention relates to a stable pharmaceutical composition comprising a therapeutically effective amount of bempedoic acid or a pharmaceutically acceptable salt thereof as a first active agent, optionally a second active agent(s), and one or ...
ABSTRACT OF THE INVENTION
Pharmaceutical composition comprising Rivaroxaban
The present invention relates to a stable, reproducible and bioequivalent pharmaceutical composition for oral administration containing a therapeutically effective amount of an anticoagulant agent such as Rivaroxaban or a pharmaceu...
ABSTRACT OF THE INVENTION
AN IMPROVED PROCESS FOR THE PREPARATION OF LISDEXAMPHETAMINE AND SALTS THEROF
The present invention provides an improved process for the preparation of Lisdexamphetamine of formula I or its pharmaceutically acceptable salts. Further, the present invention provides a novel intermediate...
ABSTRACT OF THE INVENTION
Pharmaceutical composition comprising Mirabegron
The present invention relates to a stable, reproducible and bioequivalent pharmaceutical composition for oral administration containing a therapeutically effective amount of beta-3 adrenergic agonist such as mirabegron or a pharmaceuti...
The present invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of elagolix or a pharmaceutically acceptable salt thereof. Further, the present invention specifically relates to a stable oral elagolix or pharmaceutically acceptable salt thereof in a tablet dosage form...
Provided herein is a pharmaceutical composition comprising glucagon-like peptide-1 (GLP-1) receptor agonist and a permeation enhancer. Particularly, there is provided stabilized pharmaceutical compositions comprising semaglutide and permeation enhancer, sodium caprylate and its process of preparation. The invention ...
ABSTRACT OF THE INVENTION
Pharmaceutical composition comprising Dabigatran
The present invention relates to a pharmaceutical composition comprising Dabigatran Etexilate or its pharmaceutically acceptable salts thereof. Further, the present invention also relates to a stable pharmaceutical composition of Dabiga...
ABSTRACT OF THE INVENTION
Pharmaceutical composition comprising Tofacitinib
The present invention relates to extended release composition of Tofacitinib or salt thereof, and process of manufacture thereof. Specifically, the present invention relates to the extended release composition comprising Tofacitinib or sa...
ABSTRACT
PHARMACEUTICAL COMPOSITION COMPRISING DEUTETRABENAZINE
The present invention relates to compositions of Deutetrabenazine having enhanced bioavailability, more specifically stable extended release compositions comprising Deutetrabenazine and pharmaceutically acceptable excipients and method of manufact...
The present invention relates to a pharmaceutical composition for oral administration containing a therapeutically effective amount of Zonisamide or a pharmaceutically acceptable salt thereof, and a method for the preparation thereof. The invention also relates to the use of said composition as adjunctive therapy fo...
Copyrights
Registered Trademarks
[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements
[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements
[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements
View +4056 more Brands for Alkem Laboratories Limited.
Charges
07 October 2023
Bank Of India
0
24 August 2023
Others
0
20 April 2023
Others
0
27 March 2023
Hdfc Bank Limited
0
03 April 2023
State Bank Of India
0
24 February 2023
Canara Bank
0
07 February 2023
Others
0
03 January 2023
Others
0
22 December 2022
Others
0
01 December 2022
Others
0
05 October 2022
Others
0
12 August 2016
Others
0
03 August 1999
State Bank Of India
0
27 September 2005
State Bank Of India
0
29 January 2016
Housing Development Finance Corporation Limited
0
27 February 2015
Dena Bank
0
06 March 2014
Dbs Bank Ltd.
0
28 January 2011
Bnp Paribas
0
08 July 2010
Barclays Bank Plc
0
12 September 2007
Member Secretary Single Window Clearance Agency
0
14 June 2007
Himachal Pradesh State Industrial Development Corporation Limited
0
04 March 2022
Others
0
22 February 2022
State Bank Of India
0
07 February 2022
Bank Of India
0
18 November 2021
Canara Bank
0
23 March 2022
Others
0
29 December 2021
Others
0
03 April 2021
Hdfc Bank Limited
0
23 June 2021
Canara Bank
0
21 August 2020
Others
0
24 November 2021
Hdfc Bank Limited
0
08 December 2020
Others
0
17 March 2020
Others
0
28 February 2020
Others
0
15 July 2015
Others
0
29 January 2016
Others
0
11 November 2016
Others
0
31 August 2020
Hdfc Bank Limited
0
02 June 2015
Citi Bank N.a.
0
03 November 2019
Others
0
13 September 2019
State Bank Of India
0
12 April 2019
Axis Bank Limited
0
12 December 2018
Hdfc Bank Limited
0
09 January 2020
State Bank Of India
0
